NYHA Heart Failure Classification

Why use it

Universally accepted standard for heart failure functional classification. Required for guideline-directed medical therapy (GDMT) eligibility. Used in most HF clinical trials as inclusion criterion and endpoint. Guides initiation of ICD, CRT, transplant listing, and palliative care referral. Correlates with prognosis and mortality.

About

The New York Heart Association (NYHA) Functional Classification is a four-tier system that categorizes patients with heart failure based on the relationship between symptoms and level of physical exertion. It is the universally accepted standard for assessing functional impairment in heart failure across cardiology guidelines, clinical trials, and drug labeling. Classes range from I (no limitation) to IV (symptoms at rest).

When to use

• Initial heart failure assessment and classification
• Response monitoring to GDMT (at each visit)
• Determining eligibility for ICD, CRT-D, cardiac resynchronization therapy
• Cardiac transplant candidacy assessment
• Palliative care referral decision-making
• Clinical trial eligibility assessment

Formula

Pearls & pitfalls

• NYHA class is subjective but has strong prognostic value — 1-year mortality is ~5–10% for class II, 20–30% for class III, and >50% for class IV.
• Most GDMT trials enrolled class II–III patients — efficacy data in class IV is more limited.
• ICD is indicated in HFrEF (EF ≤ 35%) with NYHA class II–III on optimal medical therapy.
• CRT is indicated in NYHA class II–III (or ambulatory IV) with EF ≤ 35% and LBBB/QRS ≥ 130 ms.
• Cardiac transplant listing typically requires persistent NYHA class III–IV despite optimal medical therapy.
• NYHA class can change with treatment — reassess at every visit.

Next steps

Class I: Focus on risk factor control and prevention of progression. Class II: Initiate/optimize GDMT (ACEi/ARNi, BB, MRA, SGLT2i). Class III: Optimize GDMT; consider ICD, CRT if EF ≤ 35%; evaluate for advanced HF therapies. Class IV: Advanced HF therapies (LVAD, transplant); palliative care; hospice evaluation.

Evidence

NYHA classification developed in 1928, updated 1994. Validated as independent predictor of mortality in HF in the CHARM, MERIT-HF, CIBIS-II, and multiple other landmark trials. Endorsed by ACC/AHA, ESC, and all major cardiac societies.

References

1. New York Heart Association Criteria Committee. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston: Little Brown; 1964. — link
2. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. — link